Quantcast

Latest Recombinant proteins Stories

2014-09-18 08:29:16

Denmark's Crown Prince Couple Help Celebrate Canadian, Danish Partnership, Marking Novo Nordisk's 30 Years in Canada MISSISSAUGA, ON, Sept. 18, 2014 /CNW/ - Danish-based pharmaceutical company Novo Nordisk, in collaboration with the Royal Danish Consulate General and the Canadian Diabetes Association (CDA), is hosting "Innovation in Diabetes Care: 90 Years and Beyond" at the MaRS Discovery District today, to highlight the significant contribution Canada has made to diabetes care, and...

2014-09-17 12:27:09

- Three-year findings regarding prophylaxis versus on-demand treatment in adults with hemophilia A WHIPPANY, N.J., Sept. 17, 2014 /PRNewswire/ -- Bayer HealthCare will present data on hemophilia A research at the National Hemophilia Foundation's 66(th) Annual Meeting, which takes place September 18-20 in Washington, D.C. The data, which will be shared through poster presentations, showcase Bayer's commitment to advancing hemophilia A treatment and patient care. Data will be presented in a...

2014-09-16 08:29:41

Clinical Trials Mark Important Milestone in Development of Two Highly Complex Products PITTSBURGH, Sept. 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus® and its insulin analog to Sanofi's Lantus®. http://photos.prnewswire.com/prnvar/20140423/77793 In October 2014, Mylan will commence a Phase III...

2014-09-11 23:06:37

Transparency Market Research published a new report "Global and China Insulin Market: Industry Analysis, Size, Share, Growth, Trends and Forecast (Value and Volume) 2013 - 2019" to its report store. Albany, New York (PRWEB) September 11, 2014 According to a new market report published by Transparency Market Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and Human Insulin) - Industry Analysis, Size,...

2014-09-10 08:29:47

Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif., Sept. 10, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced plans to submit an Investigational New Drug (IND) application for the treatment of hemophilia B in the second quarter of 2015. This program, partnered with Shire, is the first therapeutic application of Sangamo's zinc finger nuclease (ZFN)-mediated In Vivo Protein Replacement Platform (IVPRP). Sangamo is...

2014-09-09 23:05:29

Transparency Market Research published a new report "Endocrine Testing Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Albany, New York (PRWEB) September 09, 2014 The endocrine system is comprised of endocrine glands as well as secretor organs that are responsible for releasing hormones into the blood stream directly. The proper functioning of the endocrine system is central to the regulation of various important body...

2014-09-09 08:31:17

INDIANAPOLIS, Sept. 9, 2014 /PRNewswire/ -- Fifty abstracts designed to advance knowledge in diabetes science will be presented Sept. 15-19 by Eli Lilly and Company (NYSE: LLY) at the 50(th) European Association for the Study of Diabetes (EASD) Annual Meeting. Notably, the company is highlighting two of its late-stage products: basal insulin peglispro and once-weekly dulaglutide. Twenty-eight of the abstracts will be presented as part of the Boehringer Ingelheim-Lilly Diabetes Alliance. EASD...

2014-09-05 16:22:59

LifeScienceIndustryResearch.com adds "Market Research Report on Global and Chinese Insulin (API & Injection) Industry, 2009-2019" to its store. DALLAS, Sept. 5, 2014 /PRNewswire-iReach/ -- This is a professional and in-depth market survey on Global and Chinese Insulin (API & Injection) industry. The report firstly reviews the basic information of Insulin (API & Injection) including its classification, application and manufacturing technology. The report then explores global...

2014-09-04 08:30:19

Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators INDIANAPOLIS, Sept. 4, 2014 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus(®)) at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. Patients in these...

2014-08-26 08:30:42

- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions - MISSISSAUGA, ON, Aug. 26, 2014 /CNW/ - Today Biogen Idec (NASDAQ: BIIB) announces that Health Canada has approved ELOCTATE(TM) [Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein] for the control and prevention of bleeding episodes and routine prophylaxis in adults and children aged 12 and older with hemophilia A.(1) ELOCTATE is...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'